Table 1.
Patient and disease characteristics in ATL cases.
| Clinical characteristics (n=22) | ||
| Age median (range) | 65 (46-80) | |
| Sex | ||
| Male (%) | 8 (36) | |
| Subtype | ||
| Lymphoma | 6 | |
| Acute | 16 | |
| sATL-PI | ||
| Low | 0 | |
| Intermediate | 13 | |
| High | 9 | |
| Median numbers of prior regimens including allo-SCT (range) | 1 (1-3) | |
| Allo-SCT (%) | 1 (5) | |
| Clincal status prior mogamulizumab | ||
| PR | 3 | |
| PD | 19 | |
| Response after 4 cycles of mogamulizumab | ||
| CR | 8 | |
| PR | 7 | |
| SD | 2 | |
| PD | 5 | |
| Best over all response during mogamulizumab | ||
| CR | 8 | |
| PR | 7 | |
| SD | 2 | |
| PD | 5 | |
| Pathological findings (n=14) | ||
| CD3, positive (%) | 13 (93) | |
| CD4, positive (%) | 11 (79) | |
| CD8, positive (%) | 2 (14) | |
| FOXP3, positive (%) | 5 (36) | |
| CCR4, positive (%) | 12 (86) | |
| CCR4 global score, average (range) | 6.5 (0-12) | |
| HLA class1, positive (%) | 10 (71) | |
| HLA class2, positive (%) | 6 (43) | |
| PDL1, positive in neoplastic cells (%) | 2 (14) | |
| PDL1, positive in microenvironment (%) | 7 (50) | |
| PD-1 positive TIL, counts/HPF average (range) | 3.8 (0-20) |
sATL-PI: simplified Adult T-cell leukemia/lymphoma prognostic index, SCT: stem cell transplantation, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, TIL: tumor-infiltrating lymphocyte